Cancer Clinical Trials

When the way forward isn’t clear…

Maybe a clinical trial is right for you.

If you or a loved one has cancer and the current treatment option isn’t working, a clinical trial might be right for you. Clinical trials offer the latest therapy to improve on the standard of care and to test how new medical approaches work when other methods have failed. Clinical treatments have resulted in new treatments and prevention options for cancer care.

Participation in a cancer clinical trial also offers more interactive, precise and personalized care for you. Your treatment team is broader, coming from a range of disciplines. This allows more individualized attention to your care. A Phase I clinical trial can also allow you to stay closer to your home setting without having to travel to another destination.

If you are interested in learning more about a clinical trial, complete the form below or call (864) 920-2523. (This number is answered Monday through Friday, 8:30 a.m. to 5 p.m.  Please leave a voice message after business hours and your call will be returned within two business days.)

View below all of our active clinical trials.

Request Information on Clinical Trials

Someone will contact you within two business days.

How May We Help You?

Contact us: (864) 920-2523

Monday through Friday, 8:30 a.m. to 5 p.m.
or leave a message after business hours.

Learn more about Clinical Trials

Learn more about clinical trials supported by National Cancer Institute (NCI) in this brief video.

Clinical Trials Available

Current Clinical Trials

Disease Site Study Location
Disease Site: Lymphoma

USO 16065/TG Therapeutics UTX-TGR-205   View on ClinicalTrials.gov
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (UTX-TGR-205)

OP Cancer Institute Research
864-241-6251
Disease Site: AML or MDS

Aileron ALRN-6924-1-02   View on ClinicalTrials.gov
A phase 1/1b open-label study to determine the safety and tolerability of ALRN-6924 alone and in combination with cytarabine (Ara-C) in patients with relapsed/refractory acute myeloid leukemia or advanced myelodysplastic syndrome with wild-type TP53

GHS-ITOR
864-455-3600
Disease Site: Supportive Care

URCC 16092   View on ClinicalTrials.gov
Phase II Study of Exercise and Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy

OP Cancer Institute Research
864-241-6251
Disease Site: Colorectal

Daiichi DS8201-A-J203   View on ClinicalTrials.gov
A Phase 2, Multicenter, Open-Label Study Of DS-8201A In Subjects With HER2-Expressing Advanced Colorectal Cancer

OP Cancer Institute Research
864-241-6251
Disease Site: Breast or GYN

NRG CC004   View on ClinicalTrials.gov
PHASE II DOUBLE BLIND DOSE FINDING TRIAL OF BUPROPION VERSUS PLACEBO FOR SEXUAL DESIRE IN WOMEN WITH BREAST OR GYNECOLOGIC CANCER

OP Cancer Institute Research
864-241-6251
Disease Site: Breast

ALLIANCE A011502   View on ClinicalTrials.gov
A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSTIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL

OP Cancer Institute Research
864-241-6251
Disease Site: Solid Tumors

Abbvie M16-074   View on ClinicalTrials.gov
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects with Locally Advanced or Metastatic Solid Tumors. Allowed diagnosis as follows: TNBC, HNSCC relapsed/refractory to anti-PD-1/PD-L1 cancers

GHS-ITOR
864-455-3600
Disease Site: Lung Non Small Cell

SWOG LungMAP   View on ClinicalTrials.gov
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

OP Cancer Institute Research
864-241-6251
Disease Site: Melanoma

CTSU EA6134   View on ClinicalTrials.gov
A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma

OP Cancer Institute Research
864-241-6251
Disease Site: Breast

SWOG S1416   View on ClinicalTrials.gov
PHASE II RANDOMIZED PLACEBO-CONTROLLED TRIAL OF CISPLATIN WITH OR WITHOUT ABT-888 (VELIPARIB) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER AND/OR BRCA MUTATION-ASSOCIATED BREAST CANCER

OP Cancer Institute Research
864-241-6251